LyfeSci Research & Innovation

What LyfeSci Research & Innovation does

LyfeSci Research & Innovation is a private, AI-powered contract research organization (CRO) founded in 2025 and headquartered in Lincolnshire, Illinois. The company delivers end-to-end clinical research services for biotechnology and pharmaceutical sponsors, spanning pre-clinical consulting, early clinical development (Phase I), late-phase development (Phase II-III), post-marketing surveillance, and real-world evidence studies. Its service portfolio covers nine core capabilities: Early Discovery, Clinical Development, Pharmacovigilance, Clinical Pharmacology, Biostatistics, Clinical Data Management, Regulatory Affairs, Decentralized Trials, and Medical Writing, with specialization in six therapeutic areas including Neurosciences, Novel Treatments (cell and gene therapy, protein-degraders), Pediatrics, Oncology, and Cardiometabolic.

The company operates a physician-led model under Founder and CEO Dr. Tapan Parikh (a board-certified psychiatrist) and CMO Dr. William E. Gannon Jr. (35+ years of clinical trial experience). Its technology stack includes an AI-driven clinical research platform, advanced analytics for patient recruitment optimization, decentralized trial tools (eConsent, eCOA/ePRO, remote monitoring, telemedicine), and CDISC-compliant electronic data capture with FDA 21 CFR Part 11 validated audit trails. LyfeSci generates revenue through custom professional service agreements scoped per study, with no standardized pricing disclosed. In January 2026, the company acquired Clinically Media to integrate patient recruitment directly into its CRO model, expanding capabilities across dermatology, neurology, and psychiatry. Marketing is driven by content (blog, webinars, case studies, Clinical Framework Guide) and a multi-channel digital presence targeting enterprise biotech and pharma sponsors.

Name

LyfeSci Research & Innovation

Legal name

LyfeSci Research & Innovation

Website

https://lyfesci.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

LyfeSci Research & Innovation is an AI-powered contract research organization founded in 2025, offering end-to-end clinical research services to biotechnology and pharmaceutical sponsors across six therapeutic areas, with patient recruitment integrated via its Clinically Media acquisition.

Ownership category

akta.pro rank

Product category

Contract Research Organization (CRO) / Clinical Research Services

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417)

SIC

Services-Engineering, Accounting, Research, Management (8700), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

akta.pro secondary industries

Clinical Operations & Monitoring FSP (CRA/CTM/Start-up) (HLAGAOAA), Real-World Data (RWD) / Real-World Evidence (RWE) & Observational Research Platforms (HLACAOAM)

Keywords

• Contract research organization
• Clinical trial services
• Patient recruitment
• Regulatory affairs consulting
• Pharmacovigilance services

Headquarters

HQ city

Lincolnshire

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Others

Revenue model

1. Clinical Research Services (CRO): Full-service Contract Research Organization providing comprehensive clinical research services including pre-clinical consulting, early clinical development (Phase I), late-phase development (Phase II-III), post-marketing surveillance, patient recruitment, and regulatory affairs
2. Specialized Consulting Services: Expert consulting across early discovery, clinical pharmacology, regulatory strategy, pharmacovigilance, biostatistics, medical writing, and site operations delivered through a consulting model with access to seasoned drug hunters, translational scientists, and physician investigators

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

LyfeSci is an AI-powered Contract Research Organization providing end-to-end clinical research services for biotech and pharmaceutical sponsors. Its core offerings span Early Discovery consulting, Clinical Development (Phases I–III), Pharmacovigilance, Clinical Pharmacology, Biostatistics, Clinical Data Management, Regulatory Affairs, Decentralized Trials, and Medical Writing, supported by dedicated Patient Recruitment Services. Services are delivered under custom professional service agreements with tailored scopes of work, deliverables, and timelines.

Product overview

LyfeSci Research & Innovation is an AI-powered Contract Research Organization (CRO) offering a unified platform of clinical research services. The core offerings include Early Discovery consulting, Clinical Development (Phases I-III), Pharmacovigilance, Clinical Pharmacology, Biostatistics, Clinical Data Management, Regulatory Affairs, Decentralized Trials, and Medical Writing—all accessible through Patient Recruitment Services. The portfolio integrates end-to-end capabilities from preclinical consulting through post-marketing Real-World Evidence, supported by a Clinical Framework Guide methodology and educational webinars. Case studies demonstrate specialized expertise in rare disease, oncology, and cardiometabolic therapeutic areas.

Differentiator

Problem solved

Functional benefit

Products and services

• Early Discovery Strategic consulting services guiding biotech and pharmaceutical innovators through early drug discovery stages, from target identification to preclinical candidate validation, including IND pathway preparation.
• Clinical Development
• Pharmacovigilance
• Clinical Pharmacology
• Biostatistics
• Clinical Data Management
• Regulatory Affairs
• Decentralized Trials
• Medical Writing
• Patient Recruitment Services End-to-end patient enrollment solutions spanning site feasibility, patient database management, regulatory compliance, accelerated enrollment, global recruitment across 25+ countries, and quality assurance, with continuous 24/7 support.

Quantifiable outcome

• 30-50% reduction in patient recruitment timelines
• +3 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature4 records

Partnerships

One partnership is on record.

• Clinically MediacoreStrategic or Co-development Partner · 12 January 2026LyfeSci acquired Clinically Media, a patient recruitment company specializing in data-driven and inclusive enrollment strategies. The acquisition integrates patient recruitment directly into LyfeSci's CRO model, expanding end-to-end clinical trial capabilities. Clinically Media operates under the LyfeSci Research & Innovation brand with its team fully integrated into LyfeSci's services.

Scale indicators5 records

Recent moves5 records

Expansion highlights5 records

Broad incumbents

• Parexel: Large global CRO with deep biopharma sponsor relationships, regulatory expertise, and DCT capabilities (via its partnership network). Comparable to LyfeSci at the high end of the CRO market.
• ICON plc: Major global CRO offering Phase I–IV services, decentralized trials, and labs across all therapeutic areas. Represents the entrenched large-CRO competitor LyfeSci must differentiate against.
• WCG: Provider of clinical trial services and site/network enablement including IRB, technology, and patient-recruitment solutions. Comparable as an established player offering adjacent recruitment and site-empowerment services.
• IQVIA: Largest global full-service CRO and life-science technology provider. Broad incumbent whose preferred-provider agreements and global scale define the competitive ceiling for boutique CROs like LyfeSci.

Direct peers

• Reify Health: Operator of the StudyTeam and Care Access platforms for clinical trial enrollment and site performance. Highly comparable to LyfeSci's integrated patient-recruitment capabilities following the Clinically Media acquisition.
• Medable: Decentralized clinical trial platform offering eCOA/ePRO, eConsent, telehealth, and remote monitoring for sponsors and CROs. Directly comparable to LyfeSci's DCT and AI-platform positioning, with similar target customers in biotech and mid-pharma.
• Science 37: Metaverse/DCT-enabled virtual CRO running decentralized trials with patient-centric recruitment. Comparable as a technology-led CRO competing on speed, recruitment, and decentralized trial execution.
• Thread Research: Decentralized clinical trial platform combining technology and operational services for sponsors. Comparable in delivering hybrid trials with patient-centric recruitment and data capture.
• ObvioHealth: Digital CRO delivering fully decentralized and hybrid clinical trials across therapeutic areas including CNS and rare disease. Closely aligned with LyfeSci's DCT stack, CNS focus, and AI-driven recruitment approach.
• Castor: Cloud-based EDC and eClinical platform supporting decentralized and hybrid trials. Comparable to LyfeSci's CDISC-compliant data management, EDC, and DCT tooling layer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/lyfesci-research-innovation

Compliance8 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about LyfeSci Research & Innovation